Cross-Sector entity
Amprius Technologies is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. Coverage clusters in market-trends, which accounts for 1 of those 3, with the remainder spread across 2 other categories. Each carries 2 original sources on average.
3 verified stories tracked
Last mentioned: Mar 4, 2026
Entity pulse
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Amprius Technologies is the most frequent co-covered peer, appearing in 3 of the 3 tracked stories. Coverage clusters in market-trends, which accounts for 1 of those 3, with the remainder spread across 2 other categories. Each carries 2 original sources on average. We currently track 3 Cross-Sector stories that mention Keros Therapeutics, all published on March 4, 2026.
Computed from the 3 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering Keros Therapeutics. Shared-story counts are live from our verified record — not editorial picks.
FY 2025 Earnings
Released full-year financial results and updated 2026 clinical guidance.
FY2025 Earnings
Released full-year results highlighting commercial scaling and Colorado facility progress.
Anticipated Data
Expected top-line data readouts for multiple Phase 2 programs.
Brighton Fab Launch
Expected commencement of high-volume manufacturing in Colorado.
Cibotercept Progress
Initiated additional cohorts in PAH studies to evaluate dose-response.
KER-050 Expansion
Initiation of the global Phase 2/3 trial for elritercept in lower-risk MDS.
500 Wh/kg Milestone
Verified performance of 500 Wh/kg cells with key aerospace partners.
Trial Expansion
Keros expanded the TROPOS trial to include broader MDS patient populations.
Capital Infusion
Keros raised $140 million in a follow-on offering to fund late-stage TGF-beta trials.
Amprius Technologies reported its full-year 2025 financial results, highlighting a critical transition from pilot-scale production to industrial commercialization of its high-energy silicon anode batteries. The company is positioning its ultra-high-density storage solutions as the primary enabler for the burgeoning eVTOL and defense aviation sectors.
Keros Therapeutics reported robust fourth-quarter and full-year 2025 financial results, highlighting significant clinical progress across its TGF-β superfamily pipeline. The company remains well-capitalized to advance its lead assets, elritercept and cibotercept, through critical Phase 2 and Phase 3 milestones in 2026.
Keros Therapeutics reported its full-year 2025 results, highlighting significant clinical progress in its TGF-β protein superfamily pipeline for hematologic and cardiovascular disorders. The company maintains a robust cash position to fund pivotal trials for elritercept and cibotercept through key upcoming data readouts in 2026.
Source: lasvegassun.com · manilatimes.net
